Claims for Patent: 11,633,528

Summary for Patent: 11,633,528

Title:	Apparatus for removing chemotherapy compounds from blood
Abstract:	A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.
Inventor(s):	Daniel S. Johnston, Jacques Chammas, William M. Appling, Samantha J. Barton
Assignee:	Delcath Systems Inc
Application Number:	US17/557,867
Patent Claims:	1. A percutaneous hepatic perfusion procedure for treating a patient with a liver cancer, comprising: isolating blood flow from the liver with catheters to obtain an isolated liver; delivering a chemotherapy agent to the isolated liver; perfusing the chemotherapy agent in the isolated liver for a period of time sufficient to provide a therapeutic effect; filtering blood drained from the isolated liver after perfusing with a filter comprising hemocompatible polymer coated carbon cores, wherein the carbon cores have a pore volume of about 1.68 cc/g to about 2.19 cc/g, to provide filtered blood, and returning the filtered blood to the patient. 2. A percutaneous hepatic perfusion procedure according to claim 1, wherein the carbon cores have a particle diameter of about 0.45 mm to about 1.15 mm. 3. A percutaneous hepatic perfusion procedure according to claim 1, wherein the carbon cores have an apparent density of about 0.19 g/cc to about 0.2 g/cc. 4. A percutaneous hepatic perfusion procedure according to claim 1, wherein the carbon cores have an apparent density of less than 0.2 g/cc. 5. A percutaneous hepatic perfusion procedure according to claim 1, wherein the hemocompatible polymer coated carbon cores are coated with a semipermeable polymer, the semipermeable polymer comprised of material selected from the group consisting of cellulose, a methacrylate polymer and combinations thereof. 6. A percutaneous hepatic perfusion procedure according to claim 5, wherein the semipermeable polymer is a methacrylate selected from the group consisting of polymethylmethacrylate (PMMA), polyethylmethacrylate (PEMA), polyhydroxyethyl-methacrylate (PHEMA) and combinations thereof. 7. A percutaneous hepatic perfusion procedure according to claim 1, wherein the chemotherapy agent is melphalan hydrochloride. 8. A percutaneous hepatic perfusion procedure for treating a patient with a liver cancer, comprising: isolating blood flow from the liver with catheters to provide an isolated liver; delivering a chemotherapy agent to the isolated liver; perfusing the chemotherapy agent in the isolated liver for a period of time sufficient to provide a therapeutic effect; filtering blood drained from the isolated liver after perfusing with a filter comprising hemocompatible polymer coated carbon cores, wherein the carbon cores have an apparent density of about 0.19 g/cc to about 0.2 g/cc, to provide filtered blood, and returning the filtered blood to the patient. 9. A percutaneous hepatic perfusion procedure according to claim 8, wherein the carbon cores have a particle diameter of about 0.45 mm to about 1.15 mm. 10. A percutaneous hepatic perfusion procedure according to claim 8, wherein the carbon cores have a median mesoporous diameter (D50,meso) of between about 30 Å to about 156 Å. 11. A percutaneous hepatic perfusion procedure according to claim 8, wherein the hemocompatible polymer coated carbon cores are coated with a semipermeable polymer, the semipermeable polymer comprised of material selected from a group consisting of cellulose, a methacrylate polymer and combinations thereof. 12. A percutaneous hepatic perfusion procedure according to claim 11, wherein the semipermeable polymer is a methacrylate selected from the group consisting of polymethylmethacrylate (PMMA), polyethylmethacrylate (PEMA), polyhydroxyethyl-methacrylate (PHEMA) and combinations thereof. 13. A percutaneous hepatic perfusion procedure according to claim 8, wherein the chemotherapy agent is melphalan hydrochloride. 14. A percutaneous hepatic perfusion procedure according to claim 8, wherein the filter removes melphalan hydrochloride from the blood with an efficiency greater than 98% for in an in vitro system where blood flow through the filter at about 500 mL/min. 15. A percutaneous hepatic perfusion procedure for treating a patient with a liver cancer, comprising: isolating blood flow from the liver with catheters to provide an isolated liver; delivering a chemotherapy agent to the isolated liver; perfusing the chemotherapy agent in the isolated liver for a period of time sufficient to provide a therapeutic effect; filtering blood drained from the isolated liver after perfusing with a filter comprising hemocompatible polymer coated carbon cores, wherein the carbon cores have an apparent density less than about 0.2 g/cc, to provide filtered blood, and returning the filtered blood to the patient. 16. A percutaneous hepatic perfusion procedure according to claim 15, wherein the carbon cores have a median microporous diameter (D50,micro) of between about 9.3 Å to about 10.5 Å. 17. A percutaneous hepatic perfusion procedure according to claim 15, wherein the carbon cores have a median mesoporous diameter (D50,meso) of between about 30 Å to about 156 Å. 18. A percutaneous hepatic perfusion procedure according to claim 15, wherein the carbon cores have a particle diameter of about 0.45 mm to about 1.15 mm. 19. A percutaneous hepatic perfusion procedure according to claim 15, wherein the hemocompatible polymer coated carbon cores are coated with a semipermeable polymer, the semipermeable polymer comprised of material selected from a group consisting of cellulose, a methacrylate polymer and combinations thereof. 20. A percutaneous hepatic perfusion procedure according to claim 19, wherein the semipermeable polymer is a methacrylate selected from the group consisting of polymethylmethacrylate (PMMA), polyethylmethacrylate (PEMA), polyhydroxyethyl-methacrylate (PHEMA) and combinations thereof. 21. A percutaneous hepatic perfusion procedure according to claim 15, wherein the chemotherapy agent is melphalan hydrochloride. 22. A percutaneous hepatic perfusion procedure according to claim 15, wherein the filter removes melphalan hydrochloride from the blood with an efficiency greater than 98% for in an in vitro system where blood flow through the filter at about 500 mL/min. 23. A percutaneous hepatic perfusion method for treating a patient with a liver cancer, comprising: isolating blood flow from the liver with catheters to provide an isolated liver; administering a chemotherapy agent arterially to the isolated liver; perfusing the chemotherapy agent in the isolated liver for a period of time sufficient to provide a therapeutic effect; filtering blood drained from the isolated liver after perfusing with a filter comprising hemocompatible polymer coated carbon cores, wherein the carbon cores have an apparent density of is less than about 0.2 g/cc, to provide filtered blood, and returning the filtered blood to the patient. 24. A percutaneous hepatic perfusion method according to claim 23, wherein the apparent density of the carbon cores is about 0.19 g/cc to about 0.2 g/cc. 25. A percutaneous hepatic perfusion method according to claim 23, wherein the carbon cores have a pore volume of about 1.68 cc/g to about 2.19 cc/g. 26. A percutaneous hepatic perfusion method according to claim 23, wherein the carbon cores have a particle diameter of about 0.45 mm to about 1.15 mm. 27. A percutaneous hepatic perfusion method according to claim 23, wherein the chemotherapy agent is melphalan hydrochloride. 28. A filter media comprising: hemocompatible polymer coated carbon cores, the carbon cores having a pore volume of about 1.68 cc/g to about 2.19 cc/g, a particle diameter of about 0.45 mm to about 1.15 mm, and an apparent density of about 0.19 g/cc to about 0.2 g/cc, and wherein the hemocompatible polymer is a semipermeable polymer selected from a group consisting of cellulose, a methacrylate polymer and combinations thereof. 29. A filter media according to claim 28, wherein the semipermeable polymer is a methacrylate selected from the group consisting of polymethylmethacrylate (PMMA), polyethylmethacrylate (PEMA), polyhydroxyethyl-methacrylate (PHEMA) and combinations thereof.